The Federal Medical and Biological Agency (FMBA) of Russia has received a patent for a “MIR-19” drug for coronavirus that can be administered through the nose or by inhalation. This is reported on the organization’s website.
New drug developed on behalf of the head of the FMBA Veronika Skvortsova. “MIR-19” is a unique drug based on the use of microRNA. It is safe for humans, does not affect the human genome and immunity, but it is highly effective in “turning off” the copying (replication) of the virus and prevents the most severe forms of coronavirus infection, including preventing pneumonitis, acute respiratory distress syndromes against the background of coronavirus infection”, – Skvortsova said.
The agency also reported that on April 10, the authoritative European scientific journal of the European Academy of Allergy and Clinical Immunology (EAACI) “Allergy: European Journal of Allergy and Clinical Immunology” published an article by employees of the “Institute of Immunology” of the FMBA “Inhibition of reproduction of SARS-CoV-2 with a modified miRNA drug in combination with a dendrimer peptide”. It describes a therapeutic strategy for COVID-19, “based on the inhalation of modified miRNA in combination with a dendrimer peptide”.